Alphatec (NASDAQ:ATEC) Major Shareholder Squadron Capital Llc Sells 250,000 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) major shareholder Squadron Capital Llc sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total transaction of $5,200,000.00. Following the transaction, the insider owned 11,145,045 shares in the company, valued at approximately $231,816,936. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Alphatec Stock Performance

ATEC stock traded down $0.46 during trading on Friday, hitting $19.74. The company had a trading volume of 2,603,589 shares, compared to its average volume of 2,130,456. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm has a 50-day moving average price of $16.06 and a 200-day moving average price of $13.88. Alphatec Holdings, Inc. has a 1-year low of $8.18 and a 1-year high of $21.16. The firm has a market cap of $2.93 billion, a PE ratio of -17.47 and a beta of 1.17.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.09. The business had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. During the same period in the prior year, the business earned ($0.28) earnings per share. The firm’s quarterly revenue was up 30.4% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. On average, analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Hedge Funds Weigh In On Alphatec

Institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas acquired a new position in shares of Alphatec in the 1st quarter valued at $158,000. Envestnet Asset Management Inc. grew its position in Alphatec by 1.2% during the first quarter. Envestnet Asset Management Inc. now owns 390,414 shares of the medical technology company’s stock valued at $3,959,000 after acquiring an additional 4,754 shares during the period. New York State Common Retirement Fund increased its stake in Alphatec by 1.8% during the first quarter. New York State Common Retirement Fund now owns 1,224,005 shares of the medical technology company’s stock worth $12,411,000 after acquiring an additional 21,671 shares during the last quarter. CWM LLC raised its holdings in shares of Alphatec by 67.2% in the 1st quarter. CWM LLC now owns 31,336 shares of the medical technology company’s stock worth $318,000 after purchasing an additional 12,598 shares during the period. Finally, Larson Financial Group LLC acquired a new position in shares of Alphatec in the 1st quarter valued at about $54,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $25.00 target price (up from $20.00) on shares of Alphatec in a report on Friday, October 31st. Wells Fargo & Company boosted their target price on Alphatec from $14.00 to $16.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Morgan Stanley raised their price target on Alphatec from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Wall Street Zen upgraded shares of Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Needham & Company LLC raised their target price on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 31st. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $22.00.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.